147 related articles for article (PubMed ID: 33247328)
1. Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival.
Chantadisai M; Kulkarni HR; Baum RP
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1390-1398. PubMed ID: 33247328
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.
Goncalves I; Burbury K; Michael M; Iravani A; Ravi Kumar AS; Akhurst T; Tiong IS; Blombery P; Hofman MS; Westerman D; Hicks RJ; Kong G
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1902-1910. PubMed ID: 31187162
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.
Sonbol MB; Halfdanarson TR; Hilal T
JAMA Oncol; 2020 Jul; 6(7):1086-1092. PubMed ID: 32297906
[TBL] [Abstract][Full Text] [Related]
4. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
5. Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.
Werner RA; Ilhan H; Lehner S; Papp L; Zsótér N; Schatka I; Muegge DO; Javadi MS; Higuchi T; Buck AK; Bartenstein P; Bengel F; Essler M; Lapa C; Bundschuh RA
Mol Imaging Biol; 2019 Jun; 21(3):582-590. PubMed ID: 30014345
[TBL] [Abstract][Full Text] [Related]
6. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of
Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
[TBL] [Abstract][Full Text] [Related]
8. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
10. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.
Thang SP; Lung MS; Kong G; Hofman MS; Callahan J; Michael M; Hicks RJ
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):262-277. PubMed ID: 28894897
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study.
Zacho MD; Iversen P; Villadsen GE; Baunwall SMD; Arveschoug AK; Grønbaek H; Dam G
Scand J Gastroenterol; 2021 Mar; 56(3):289-297. PubMed ID: 33470864
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
Akimoto M; Sakurai A; Nishiyama-Fujita Y; Ito C; Aisa Y; Nakazato T
Ann Hematol; 2021 Apr; 100(4):953-957. PubMed ID: 33521864
[TBL] [Abstract][Full Text] [Related]
13. Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Kesavan M; Turner JH
Cancer Biother Radiopharm; 2016 Aug; 31(6):189-98. PubMed ID: 27419665
[TBL] [Abstract][Full Text] [Related]
14. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of PRRT in advanced bronchopulmonary carcinoid.
Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198
[TBL] [Abstract][Full Text] [Related]
16. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis.
Strosberg J; Leeuwenkamp O; Siddiqui MK
Cancer Treat Rev; 2021 Feb; 93():102141. PubMed ID: 33418096
[TBL] [Abstract][Full Text] [Related]
17. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
18. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of
Abou Jokh Casas E; Pubul Núñez V; Anido-Herranz U; Del Carmen Mallón Araujo M; Del Carmen Pombo Pasín M; Garrido Pumar M; Cabezas Agrícola JM; Cameselle-Teijeiro JM; Hilal A; Ruibal Morell Á
World J Gastroenterol; 2020 Apr; 26(13):1513-1524. PubMed ID: 32308351
[TBL] [Abstract][Full Text] [Related]
20. Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients.
Aalbersberg EA; Huizing DMV; Walraven I; de Wit-van der Veen BJ; Kulkarni HR; Singh A; Stokkel MPM; Baum RP
J Nucl Med; 2019 Sep; 60(9):1259-1265. PubMed ID: 30850483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
